Search

Your search keyword '"Dheeraj Gautam"' showing total 3 results
Start Over Author "Dheeraj Gautam" Publisher elsevier
3 results on '"Dheeraj Gautam"'

1. Nonalcoholic Fatty Liver in Lean Individuals: Clinicobiochemical Correlates of Histopathology in 157 Liver Biopsies from Healthy Liver Donors

Author

Ajay Duseja, Arvinder S. Soin, Amit Rastogi, Prashant Bhangui, Dheeraj Gautam, Narendra S. Choudhary, Neeraj Saraf, Sanjiv Saigal, and Srinivasan Thiagrajan

Subjects
medicine.medical_specialty, Hepatology, medicine.diagnostic_test, business.industry, Fatty liver, Histology, Disease, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Liver biopsy, Biopsy, medicine, 030211 gastroenterology & hepatology, Histopathology, Original Article, Steatosis, Metabolic syndrome, business
Abstract

BACKGROUND: Generally diagnosis of non-alcoholic fatty disease is made on imaging, however, mild steatosis is difficult to diagnose on imaging. Liver biopsy is the procedure of choice but is not carried out as it is an invasive procedure. We describe our experience of 157 liver biopsies in living liver donors with normal body mass index (BMI) 150 mg/dl as compared with 12.5% in the normal histology group, p = 0.009. Other metabolic risk factors were not statistically different. CONCLUSION: One third of lean donors had NAFL. Among all metabolic risk factors, only higher TGs levels showed a significant association with NAFL.

Published
2021

2. Delayed Graft Dysfunction due to Invasive Hepatic Mucormycosis After Living Donor Liver Transplantation

Author

Tarun Piplani, Dheeraj Gautam, Rohan Jagat Chaudhary, Arvinder S. Soin, Srinivasan Thiagrajan, Neeraj Saraf, Sanjiv Saigal, Prashant Bhangui, Amit Rastogi, and Narendra S. Choudhary

Subjects
medicine.medical_specialty, Posaconazole, Graft dysfunction, Unusual case, Hepatology, medicine.diagnostic_test, business.industry, Mortality rate, medicine.medical_treatment, Mucormycosis, Immunosuppression, Case Report, medicine.disease, Surgery, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, 030211 gastroenterology & hepatology, Living donor liver transplantation, business, Liver function tests, medicine.drug
Abstract

Mucormycosis is a rare but emerging fungal infection complicating solid organ transplantation. It is associated with a high mortality rate. We describe an unusual case of hepatic mucormycosis in a living donor liver transplant recipient presenting as delayed graft dysfunction, which was successfully treated with combination of liposomal amphotericin B and oral posaconazole therapy, without surgical resection. The patient had clinical improvement with normalization of liver function tests.

Published
2020

3. Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India

Author

Arvinder S. Soin, Prashant Bhangui, Narendra S. Choudhary, Sanjay Goja, Amit Rastogi, Neeraj Saraf, Dheeraj Gautam, and Sanjiv Saigal

Subjects
medicine.medical_specialty, Treatment response, Sofosbuvir, medicine.medical_treatment, Statistical difference, Liver transplantation, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Hepatology, business.industry, Ribavirin, virus diseases, Hepatitis C, medicine.disease, Surgery, Clinical trial, chemistry, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Original Article, Living donor liver transplantation, business, medicine.drug
Abstract

INTRODUCTION: Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on “real world” experience for HCV recurrence after living donor liver transplantation (LDLT) is limited. MATERIAL AND METHODS: Consecutive 78 patients who completed Sofosbuvir based HCV treatment after liver transplantation were included. Following Sofosbuvir based regimens were used; Sofosbuvir + Ribavirin (n = 58), Sofosbuvir + Ledipasvir ± Ribavirin (n = 5), Sofosbuvir + Daclatasvir ± Ribavirin (n = 15). Treatment was given for 12 weeks (triple therapy) or 24 weeks (dual therapy). RESULTS: A total of 74/78 (94.8%) patients achieved end of treatment response (ETR) while 4 did not achieve ETR. A total of 68/76 (89.4%) patients achieved sustained virological response at 12 weeks (SVR12). while 2 are waiting for 12 weeks follow up after ETR. Twelve patients had history of failed previous treatment with Peginterferon and Ribavirin after LDLT, all these patients achieved ETR and 11/12 had SVR12. There was no statistical difference in response rates between genotype 1 or 3. Eighteen patients (16 on Ribavirin) had hemoglobin

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results